William Blair Investment Management LLC lessened its holdings in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 28.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 937,974 shares of the company’s stock after selling 373,346 shares during the quarter. William Blair Investment Management LLC’s holdings in Guardant Health were worth $167,297,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. MCF Advisors LLC increased its stake in shares of Guardant Health by 755.0% in the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after purchasing an additional 151 shares during the last quarter. NFSG Corp acquired a new position in shares of Guardant Health during the 3rd quarter worth $33,000. Jacobi Capital Management LLC bought a new stake in shares of Guardant Health during the 3rd quarter worth $35,000. Fulcrum Asset Management LLP bought a new stake in shares of Guardant Health during the 3rd quarter worth $37,000. Finally, Hollencrest Capital Management bought a new stake in shares of Guardant Health during the 1st quarter worth $41,000. Institutional investors and hedge funds own 92.60% of the company’s stock.
Insider Buying and Selling at Guardant Health
In related news, CTO Darya Chudova sold 7,738 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the completion of the sale, the chief technology officer directly owned 70,635 shares in the company, valued at $12,573,030. This represents a 9.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steve E. Krognes sold 6,674 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.74, for a total value of $1,172,888.76. Following the transaction, the director directly owned 7,906 shares of the company’s stock, valued at approximately $1,389,400.44. This represents a 45.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,039 shares of company stock worth $9,088,877 in the last three months. 5.60% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on GH shares. Stephens raised their price objective on Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Mizuho increased their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Barclays raised their price target on shares of Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Rothschild & Co Redburn initiated coverage on shares of Guardant Health in a report on Tuesday, September 8th. They set a “buy” rating and a $203.00 price target on the stock. Finally, UBS Group upped their price objective on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $190.88.
View Our Latest Stock Analysis on Guardant Health
Guardant Health Price Performance
NASDAQ:GH opened at $151.70 on Monday. The firm’s 50 day simple moving average is $168.64 and its 200 day simple moving average is $132.99. Guardant Health, Inc. has a one year low of $74.55 and a one year high of $191.05. The company has a market cap of $20.52 billion, a PE ratio of -41.22 and a beta of 1.67.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.46. The business had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. During the same quarter last year, the company posted ($0.74) earnings per share. The company’s revenue was up 36.1% compared to the same quarter last year. Equities research analysts expect that Guardant Health, Inc. will post -3.08 EPS for the current year.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Stories
- Five stocks we like better than Guardant Health
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
